Last reviewed · How we verify
Traditional Antiplatelet Therapy Control Group
Traditional antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.
Traditional antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events. Used for Acute coronary syndrome, Secondary prevention of myocardial infarction, Stroke prevention.
At a glance
| Generic name | Traditional Antiplatelet Therapy Control Group |
|---|---|
| Sponsor | Sichuan Provincial People's Hospital |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This control group represents standard-of-care antiplatelet agents (typically aspirin and/or clopidogrel) that work by irreversibly or reversibly inhibiting platelet activation and aggregation. These agents reduce the formation of pathological blood clots in cardiovascular and cerebrovascular disease by blocking platelet-to-platelet interactions and adhesion to vessel walls.
Approved indications
- Acute coronary syndrome
- Secondary prevention of myocardial infarction
- Stroke prevention
- Peripheral arterial disease
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Intracranial hemorrhage
Key clinical trials
- Based on the Spatio-temporal Coding Characteristics of Frontotemporal Network, This Paper Explores the Mechanism of Five-tone Speech Training in Reshaping Language Fluency Function. (NA)
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial (PHASE1)
- Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE） (PHASE4)
- Danhong Injection in the Treatment of Acute Ischemic Stroke (PHASE4)
- Bloodletting Puncture in the Treatment of Acute Ischemic Stroke (NA)
- Multi-"Omics" Research of Danhong Injection to Treat Acute Ischemic Stroke (PHASE4)
- Dental Extractions in Patients Under Dual Antiplatelet Therapy (NA)
- Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: